What is a feature table in a Sequence Listing XML and why is it important?
A feature table in a Sequence Listing XML is a crucial component that provides information about various regions within a particular sequence. As stated in MPEP 2413.01(g): “A feature table is required for every sequence, except for any intentionally skipped sequence, in which case it must not be included. The feature table is contained in…
Read MoreWhat does “enumeration of its residues” mean in the context of Sequence Listing XML?
According to MPEP 2412.02(a), “enumeration of its residues” refers to the disclosure of a nucleotide or amino acid sequence in a patent application by listing each residue of the sequence in order. The MPEP cites 37 CFR 1.831(d), which states: “Enumeration of its residues” means disclosure of a nucleotide or amino acid sequence in a…
Read MoreWhat does “enumeration of its residues” mean in patent applications?
“Enumeration of its residues” refers to the disclosure of a nucleotide or amino acid sequence in a patent application. According to MPEP 2412.02(a), it means: “disclosure of a nucleotide or amino acid sequence in a patent application by listing, in order, each residue of the sequence, where the residues are represented in the manner as…
Read MoreWhen did the new requirements for “specifically defined” nucleotides and amino acids come into effect?
According to MPEP 2412.03(a), the new requirements for “specifically defined” nucleotides and amino acids came into effect for patent applications filed on or after July 1, 2022. The MPEP states: [Editor Note: This section is applicable to all applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as…
Read MoreWhen did the requirements for Sequence Listing XML format come into effect?
The requirements for the Sequence Listing XML format came into effect for certain patent applications filed on or after July 1, 2022. According to the editor’s note in MPEP 2412.05(a): “[Editor Note: This section is applicable to all applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as…
Read MoreWhen did the new requirements for nucleotide and amino acid sequence disclosures in patent applications take effect?
The new requirements for nucleotide and amino acid sequence disclosures in patent applications took effect on July 1, 2022. This is clearly stated in MPEP 2412.02(a): “[Editor Note: This section is applicable to all applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR…
Read MoreWhat is a DOCTYPE declaration in a Sequence Listing XML?
A DOCTYPE declaration in a Sequence Listing XML is a specific line of code that must be included in the XML file to comply with WIPO Standard ST.26. According to MPEP 2413.01(d), the DOCTYPE declaration should be: This declaration specifies the document type and version of the Sequence Listing XML, ensuring compatibility with WIPO standards.…
Read MoreWhen did the requirement for a DOCTYPE declaration in Sequence Listing XML become effective?
The requirement for a DOCTYPE declaration in Sequence Listing XML became effective for patent applications filed on or after July 1, 2022. As stated in MPEP 2413.01(d): This section is applicable to all applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).…
Read MoreHow are modified nucleotides described in a patent application?
Modified nucleotides in patent applications are described according to MPEP 2412.05(b) as follows: Represent modified nucleotides as the corresponding unmodified nucleotides (a, c, g, t) when possible Use the symbol “n” for modified nucleotides that cannot be represented by other symbols Further describe modified nucleotides in a feature table using the feature key “modified_base” Use…
Read MoreHow should regions of consecutive modified nucleotides be described in a patent application?
According to MPEP 2412.05(b), regions of consecutive modified nucleotides in patent applications should be described as follows: Describe the region in a feature table as required for a modified nucleotide Modified nucleotides in the region can be jointly described in a single INSDFeature element Provide the most restrictive unabbreviated chemical name or a list of…
Read More